Who is sponsoring NCT04493918?

NCT04493918 is sponsored by Ahmad Jabir Rahyussalim.

What drugs are being tested in NCT04493918?

Interventions in NCT04493918: Mesenchymal Stem cell + Nacl 0.9%, NaCl 0.9%.

What condition does NCT04493918 study?

NCT04493918 studies Spinal Tuberculosis, Mesenchymal Stem Cell.

Is NCT04493918 still recruiting?

NCT04493918 is currently status unknown. Last updated 3 August 2020.

Last reviewed 2020-08-03 · How we verify

NCT04493918

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectivity of Mesenchymal Stem Cell on Vertebral Bone Defect Due to Mycobaterium Tuberculosis Infection

Status unknown Phase 2 Last updated 3 August 2020

What this trial tests

Phase 2 trial testing Mesenchymal Stem cell + Nacl 0.9% in Spinal Tuberculosis in 20 participants. Status unknown.

Timeline

21 May 2017

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Ahmad Jabir Rahyussalim
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	21 May 2017
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	1 location across Indonesia

Drugs / interventions tested

Mesenchymal Stem cell + Nacl 0.9%
NaCl 0.9%

Conditions studied

Spinal Tuberculosis — all drugs for Spinal Tuberculosis →
Mesenchymal Stem Cell — all drugs for Mesenchymal Stem Cell →

Sponsor

Ahmad Jabir Rahyussalim — full company profile →

Who can join

Adults 15 to 64, any sex, with Spinal Tuberculosis or Mesenchymal Stem Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effectiveness of locally implantation of mesenchymal stem cell on vertebral bone defects due to infection of mycobacterium tuberculosis. there are controlled participants who receives placebo and patients who receives implantation of MSc

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
The Research Progress in Immunotherapy of Tuberculosis.
Mi J, Liang Y, Liang J, Gong W, et al · · 2021 · cited 27× · PMID 34869066 · DOI 10.3389/fcimb.2021.763591
Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.
Zhang X, Xie Q, Ye Z, Li Y, et al · · 2021 · cited 10× · PMID 34367155 · DOI 10.3389/fimmu.2021.695278

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04493918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ahmad Jabir Rahyussalim
Last refreshed: 3 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04493918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing